TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9298518

Group type: EXPERIMENTAL
Intervention: Amisulpride 800 mg/day
Number of subjects: 191

Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 191
Study: 8296751

Group type: EXPERIMENTAL
Intervention: Slow balloon deflation
Number of subjects: 157

Group type: COMPARATOR
Intervention: Fast balloon deflation
Number of subjects: 157
Study: 3140995

Group type: EXPERIMENTAL
Intervention: megavoltage photon irradiation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: cyclotron-generated fast neutrons
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study: 31088421

Group type: EXPERIMENTAL
Intervention: Mindfulness-augmented 'Trampoline' programme
Number of subjects: 420

Group type: COMPARATOR
Intervention: Standard 'Trampoline' programme
Number of subjects: 420
Study: 26231584

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23677862

Group type: EXPERIMENTAL
Intervention: Early neonatal feeding (ENF)
Number of subjects: 24992

Group type: COMPARATOR
Intervention: No early neonatal feeding
Number of subjects: 24992

Group type: EXPERIMENTAL
Intervention: Perceived inability to suckle normally after birth
Number of subjects: 24992
Study: 20701024

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily, one hour before sleep (group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily, one hour before sleep (group B)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 33
Study: 18470755

Group type: EXPERIMENTAL
Intervention: Thorough QT/QTc study as per ICH E14 guidance
Number of subjects: 0
Study: 16639731

Group type: COMPARATOR
Intervention: FAC (5-fluorouracil 1000 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: FAC followed by high-dose chemotherapy (HDCT) with autologous stem cell support (ASCS) (high-dose cyclophosphamide 5250 mg/m2, etoposide 1200 mg/m2, cisplatin 165 mg/m2)
Number of subjects: 78
Study: 12631092

Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (CHr) group
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Transferrin saturation (TSAT) group
Number of subjects: 197
Study: 10722178

Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control session (sham depletion)
Number of subjects: 12
Study: 8908525

Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (Group 1, n = 48)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 100 mg daily for the first 10 days of a 21-day cycle with an oral contraceptive containing 2 mg cyproterone acetate (Group 2, n = 65)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Spironolactone (100-200 mg daily) (Group 3, n = 12)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg daily) (Group 4, n = 16)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Low-dose combined oral contraceptive (Group 1)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Cyproterone acetate (Group 2)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ketoconazole (Group 4)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Spironolactone (Group 3)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 141
Study: 1916651

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6761087

Group type: EXPERIMENTAL
Intervention: 3-day treatment with 200-mg clotrimazole suppositories
Number of subjects: 63

Group type: COMPARATOR
Intervention: 7-day treatment with 100-mg clotrimazole suppositories
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Treatment with miconazole or clotrimazole
Number of subjects: 63
Study: 31072272

Group type: COMPARATOR
Intervention: MJ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MJ+SJ
Number of subjects: 30

Group type: COMPARATOR
Intervention: AAS-MJ
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AAS-MJ+SJ
Number of subjects: 30
Study: 31060740

Group type: EXPERIMENTAL
Intervention: Ambrisentan/Tadalafil fixed-dose combination (10 mg ambrisentan + 40 mg tadalafil)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ambrisentan/Tadalafil fixed-dose combination (5 mg/20 mg)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ambrisentan/Tadalafil fixed-dose combination (5 mg/40 mg)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Reference monotherapies (Ambrisentan and Tadalafil)
Number of subjects: 112
Study: 26893457

Group type: EXPERIMENTAL
Intervention: Bilateral robotic priming combined with the task-oriented approach
Number of subjects: 31

Group type: COMPARATOR
Intervention: Task-oriented approach alone
Number of subjects: 31
Study: 26847016

Group type: EXPERIMENTAL
Intervention: Home DLMOs
Number of subjects: 32
Study: 24265330

Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 50
Study: 21074887

Group type: EXPERIMENTAL
Intervention: MI+DSME
Number of subjects: 234

Group type: COMPARATOR
Intervention: DSME alone
Number of subjects: 234
Study: 19811168

Group type: EXPERIMENTAL
Intervention: Isabel (web-based decision support system)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Not using Isabel (control group)
Number of subjects: 117
Study: 17826034

Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE) including family members
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE) directed solely at patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard care or non-specific interventions
Number of subjects: 19
Study: 15179645

Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation (PVS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 9
Study: 11440277

Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg tid subcutaneously for a maximum of 36 months)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 18
Study: 9932217

Group type: EXPERIMENTAL
Intervention: 5-day structured treatment and teaching programme (DTTP) for intensified insulin therapy
Number of subjects: 94
Study: 7829634

Group type: EXPERIMENTAL
Intervention: GH (Humatrope, Eli Lilly; 0.074 mg/kg, sc, 3 times/week; n = 9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: GH and Placebo
Number of subjects: 20
Study: 2574986

Group type: EXPERIMENTAL
Intervention: Extradural diamorphine 0.1 mg kg‐1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Extradural somatostatin 3 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 24
Study: 764996

Group type: EXPERIMENTAL
Intervention: 1 dose of acetone-inactivated and dried typhoid vaccine
Number of subjects: 35000

Group type: EXPERIMENTAL
Intervention: 2 doses of acetone-inactivated and dried typhoid vaccine
Number of subjects: 35000

Group type: COMPARATOR
Intervention: Tetanus toxoid (Control)
Number of subjects: 35000
Study: 31841100

Group type: EXPERIMENTAL
Intervention: NTEP cultivars
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: R. solani
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: R. zeae
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Genotypes with improved resistance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interaction effects with pathogen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlations between R. solani and R. zeae disease severity
Number of subjects: 20
Study: 31126528

Group type: COMPARATOR
Intervention: R-CHOP50
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: R-CEOP70
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: R-CEOP90
Number of subjects: 648
Study: 28651960

Group type: EXPERIMENTAL
Intervention: Dry culture
Number of subjects: 297

Group type: COMPARATOR
Intervention: Humidified culture
Number of subjects: 297
Study: 26250834

Group type: EXPERIMENTAL
Intervention: Helmet NIPPV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mask NIPPV
Number of subjects: 40
Study: 22633793

Group type: EXPERIMENTAL
Intervention: Mediterranean diet score (MED)
Number of subjects: 3232

Group type: EXPERIMENTAL
Intervention: Mediterranean diet score (MDS)
Number of subjects: 3232

Group type: EXPERIMENTAL
Intervention: Mediterranean style-dietary pattern score (MSDPS)
Number of subjects: 3232
Study: 21350423

Group type: EXPERIMENTAL
Intervention: Cytoflavin and basic treatment (trental and group B vitamins)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Basic treatment only
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Corticosteroids (metipred) as an add-on in pulse-treatment regime
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cytoflavin, trental, group B vitamins and corticosteroids
Number of subjects: 94
Study: 19118069

Group type: EXPERIMENTAL
Intervention: Pemetrexed 900 mg/m(2) + 75 mg/m(2) cisplatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pemetrexed 800 mg/m(2) + 75 mg/m(2) cisplatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pemetrexed (various doses)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m(2) + 75 mg/m(2) cisplatin
Number of subjects: 21
Study: 17019548

Group type: EXPERIMENTAL
Intervention: Arginine-vasopressin (AVP) (0.04-0.20 Umin(‐1), n=13)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Norepinephrine (NE) (0.1-2.8 microg kg(‐1)min(‐1), n=10)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both groups (AVP and NE)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: AVP
Number of subjects: 23
Study: 12562446

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 243

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 243
Study: 10686246

Group type: EXPERIMENTAL
Intervention: Outreach intervention (mailing with brochure and follow-up phone call)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Control group (no outreach intervention)
Number of subjects: 594
Study: 9406673

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus and impaired glucose tolerance
Number of subjects: 2875

Group type: EXPERIMENTAL
Intervention: Hypercholesterolaemia and hypertension
Number of subjects: 2875
Study: 8458365

Group type: EXPERIMENTAL
Intervention: Flecainide (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 30
Study: 4025956

Group type: EXPERIMENTAL
Intervention: Diet trial
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Diet manipulation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Double-blind challenges
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Migraine provoking challenges
Number of subjects: 43
Study: 29530257

Group type: EXPERIMENTAL
Intervention: Cognitive Preparation + Video Feedback + Audience Feedback + Cognitive Review (CP + VF + AF + CR)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cognitive Preparation + Video Feedback + Cognitive Review (CP + VF + CR)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cognitive Preparation + Video Feedback only (CP + VF)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study: 27488392

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training, 4 sessions over 4 consecutive days during a 7-day detoxification program
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham training (control group), 4 sessions over 4 consecutive days during a 7-day detoxification program
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cognitive Bias Modification (CBM) training and Sham training (control)
Number of subjects: 83
Study: 23911604

Group type: EXPERIMENTAL
Intervention: Escherichia coli 83972
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Symptomatic re‐isolates
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Symptomatic isolates
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Bacterial gene expression profiles
Number of subjects: 4
Study: 22151148

Group type: EXPERIMENTAL
Intervention: Community health nurse/peer counselor intervention
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study: 20013882

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich 2:1 dry mix of red wine and red grape juice extracts (MIX)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Only a grape juice extract (GJX)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 19094529

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with a tourniquet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total knee arthroplasty without a tourniquet
Number of subjects: 60
Study: 16241946

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (2.5 mg b.i.d.)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (5 mg b.i.d.)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (10 mg b.i.d.)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (20 mg b.i.d.)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (30 mg b.i.d.)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Enoxaparin (30 mg b.i.d.)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (all doses)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (2.5-10 mg b.i.d.)
Number of subjects: 621
Study: 12133066

Group type: EXPERIMENTAL
Intervention: Vasal lavage with 50 mL of normal saline
Number of subjects: 72

Group type: COMPARATOR
Intervention: No vasal lavage (control group)
Number of subjects: 72
Study: 10102093

Group type: EXPERIMENTAL
Intervention: Functional bracing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoprene sleeve
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACL-deficient knee
Number of subjects: 0
Study: 7554636

Group type: EXPERIMENTAL
Intervention: Arthroscopic division
Number of subjects: 40

Group type: COMPARATOR
Intervention: Arthroscopy and manipulation
Number of subjects: 40
Study: 2160414

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) injection of CY 216, 100 anti-factor Xa IC U/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) injection of CY 216, 100 anti-factor Xa IC U/kg
Number of subjects: 12
Study: 335197

Group type: EXPERIMENTAL
Intervention: co-trimoxazole
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: amoxycillin
Number of subjects: 105
Study: 31099219

Group type: EXPERIMENTAL
Intervention: Acupuncture artificial menstrual cycle method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication artificial menstrual cycle method (Femoston)
Number of subjects: 60
Study: 28829526

Group type: EXPERIMENTAL
Intervention: Morphine-ADER-IMT 60 mg
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Morphine-ADER-IMT 30 mg
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Morphine-ADER-IMT 2 ȕ 15 mg
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Morphine-ADER-IMT
Number of subjects: 115
Study: 26244354

Group type: EXPERIMENTAL
Intervention: Azelaic acid foam 15%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 23551324

Group type: EXPERIMENTAL
Intervention: UVA 15 J/cm(2) /session
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 45

Group type: COMPARATOR
Intervention: UVA 10 J/cm(2) /session
Number of subjects: 45
Study: 21756378

Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate 0.2% plus Hyaluronidase
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate 0.2%
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate 0.1%
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 19430059

Group type: EXPERIMENTAL
Intervention: EVOH fiber underwear
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (cotton underwear)
Number of subjects: 21
Study: 16919986

Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB) followed by Elective Neck Dissection (END)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB) without Elective Neck Dissection (END)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Overall Sentinel Node Biopsy (SNB) procedure
Number of subjects: 55
Study: 15117384

Group type: EXPERIMENTAL
Intervention: Informed Choice leaflets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision aid implementation packages
Number of subjects: 0
Study: 10917323

Group type: EXPERIMENTAL
Intervention: LET (lidocaine 2%, epinephrine 1:1,000, tetracaine 2%)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (epinephrine 1:1,000)
Number of subjects: 43
Study: 9048348

Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous (SC) rHuEPO at one third the weekly IV dose for 10 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard intravenous (IV) rHuEPO therapy
Number of subjects: 44
Study: 8315262

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 500 mg daily (about 8.7 mg/kg body weight)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 3443140

Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 100 mg orally
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 200 mg orally
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 20 mg as a constant‐rate intravenous infusion over 20 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Smokers (S) vs Nonsmokers (NS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Males (M) vs Females (FM)
Number of subjects: 18
Study: 28643056

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB)
Number of subjects: 34
Study: 27158851

Group type: EXPERIMENTAL
Intervention: EVOLUTION: Young Women Taking Charge and Growing Stronger (behavioral intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23980121

Group type: EXPERIMENTAL
Intervention: CPAP training for first-generation nurses
Number of subjects: 28

Group type: COMPARATOR
Intervention: CPAP training for second-generation nurses
Number of subjects: 28
Study: 23034417

Group type: EXPERIMENTAL
Intervention: Zirconia cantilever FDPs (test group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Metal-ceramic cantilever FDPs (control group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 20724647

Group type: EXPERIMENTAL
Intervention: 10 g C10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 23 g C10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 23 g C10 (substituted for fats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C10 (in L6 muscle cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C10
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g (control)
Number of subjects: 0
Study: 18272089

Group type: EXPERIMENTAL
Intervention: 24 mg dexamethasone intravenously
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 15709187

Group type: EXPERIMENTAL
Intervention: mTOR kinase inhibitor CCI‐779
Number of subjects: 45
Study: 12566371

Group type: EXPERIMENTAL
Intervention: Lisinopril (30 mg/d, median, range: 10 to 40 mg/d)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg/d)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lisinopril (maximum doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 28
Study: 10687257

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Trimetazidine (20 mg 3 times daily)
Number of subjects: 16
Study: 8684197

Group type: EXPERIMENTAL
Intervention: Midwife-managed care
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Shared care
Number of subjects: 1299
Study: 1896268

Group type: EXPERIMENTAL
Intervention: 0.1 mL/kg of 1% lidocaine prior to the lumbar puncture
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonanesthetized lumbar puncture without placebo
Number of subjects: 81
Study: 6414822

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg/day for 2.5 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydralazine 0.2 mg/kg intravenous injection after indomethacin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hydralazine 0.2 mg/kg intravenous injection after placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Indomethacin vs. Placebo
Number of subjects: 9
Study: 31326947

Group type: EXPERIMENTAL
Intervention: Updated prognostic tool based on validated risk calculators
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Sexual behaviour risk factors
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Socioeconomic risk factors
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Risk class membership
Number of subjects: 1049
Study: 31730473

Group type: EXPERIMENTAL
Intervention: Sexual and Marital Enrichment package
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine care at health centers (Control)
Number of subjects: 200
Study: 28854208

Group type: EXPERIMENTAL
Intervention: Immediate group (oral iron started concurrently with antimalarial treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed group (oral iron started 28 days after antimalarial treatment)
Number of subjects: 0
Study: 25819861

Group type: EXPERIMENTAL
Intervention: Self-management intervention conducted by a nurse focusing on medication goals, medication-symptom associations, and symptom response plan
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual care (attention control group) with unrelated follow-up calls
Number of subjects: 86
Study: 23852658

Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 1086